Ligand Pharmaceuticals Incorporated
NASDAQ:LGNDBiotechnology
+$2.89 today
- Market cap
- $5.98B
- Beta
- 1.04
- P/E (TTM)
- 34.4
- EPS (TTM)
- $7.72
Volume 0.38M
Average 0.22M
LGND Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ligand Pharmaceuticals IncorporatedNASDAQ: LGND
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables grows, but more slowly than its trailing trend
Q2 FY2026 accounts receivables of $13.85M (cash outflow) rose 400.9% year over year, behind the +513.3% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 8.1% of revenue in FY2025, up 4.2 pp from a year earlier.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +400.9% toward the trailing-twelve-month pace of +513.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (21.74M) USD
- Year-over-year change
- -236.5%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21.74M) | -236.5% |
| FY2024 | 2024-12-31 | (6.46M) | -148.3% |
| FY2023 | 2023-12-31 | (2.6M) | -104.7% |
| FY2022 | 2022-12-31 | 55.32M | +293.3% |
| FY2021 | 2021-12-31 | (28.62M) | — |
Accounts Receivables vs competitors
How LGND compares with its peers on the latest reported figures
- LGND's LTM Jun 2026 accounts receivables of $25.84M is the 7th largest of the 10 companies compared; the peer median is $29.86M.
- Its year-over-year change of +513.3% is the highest of 8, against a peer median of -9.4%.
- Accounts receivables amounts to 8.9% of revenue for LGND, versus a peer median of 2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.53B | -9.4% | +53.1% | 4.0% | |
| LTM Jun 2026 | $1.28B | +66.8% | +0.8% | 2.0% | |
| LTM Jun 2026 | $678M | +102.4% | -23.7% | 1.4% | |
| LTM Jun 2026 | $282.32M | +167.9% | +81.5% | 4.9% | |
| LTM Jun 2026 | $189.32M | — | -57.2% | 4.6% | |
| LTM Jul 2026 | $29.86M | -128.6% | — | 1.2% | |
| LTM Jun 2026 | $25.84M | +513.3% | — | 8.9% | |
| LTM Jun 2026 | $17.47M | -45.2% | +19.7% | 1.9% | |
| LTM Mar 2026 | $8.4M | -40.2% | -25.8% | 2.8% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding LGND) | $29.86M | -9.4% | +0.8% | 2.0% | |
Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 57.14M | (33.36M) | 52.15M | (4.03M) | 124.45M |
| Depreciation & Amortization | 50.95M | 43.39M | 36.52M | 35.24M | 33.78M |
| Deferred Income Tax | (8.62M) | 20.72M | 11.7M | (15.8M) | 22.68M |
| Stock-Based Compensation | 38.78M | 60.29M | 25.74M | 41.09M | 0 |
| Change in Working Capital | (52.16M) | 65.68M | (34.4M) | 19.36M | (12.67M) |
| Accounts Receivables | (28.62M) | 55.32M | (2.6M) | (6.46M) | (21.74M) |
| Inventory | (427K) | 12.06M | (10.87M) | 9.62M | 4.99M |
| Accounts Payables | (1.17M) | (3.34M) | (4.7M) | 0 | 5.88M |
| Other Working Capital | (21.96M) | 1.64M | (16.23M) | 16.2M | (1.8M) |
| Other Non-Cash Items | (7.29M) | (18.87M) | (42.14M) | 21.2M | (118.89M) |
| Operating Cash Flow | 78.8M | 137.85M | 49.58M | 97.05M | 49.36M |
| Capital Expenditures | (8.76M) | (17.92M) | (53.85M) | (19.64M) | (452K) |
| Acquisitions (Net) | 494K | (750K) | (25.65M) | (172.19M) | (8.09M) |
| Purchases of Investments | (181.33M) | (51.23M) | (126.76M) | (226.38M) | (730.86M) |
| Sales of Investments | 221.34M | 234.39M | 194.17M | 269.62M | 377.28M |
| Other Investing Activities | (1.22M) | (868K) | (49.91M) | (12.89M) | (4.34M) |
| Investing Cash Flow | 30.52M | 163.62M | (11.68M) | (143.66M) | (377.32M) |
| Debt Repayment | (146.01M) | (260.8M) | (76.9M) | (25K) | 338.11M |
| Common Stock Issued | 33.76M | 3.23M | 22.45M | 37.14M | 114.89M |
| Common Stock Repurchased | (18.45M) | 0 | 0 | 0 | (15M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.07M) | (18.42M) | (5.5M) | 60.03M | (9.77M) |
| Financing Cash Flow | (137.76M) | (275.99M) | (59.95M) | 97.14M | 428.22M |
| Effect of Forex Changes | 0 | 0 | 0 | (1.17M) | 2.36M |
| Net Change in Cash | (28.44M) | 25.48M | (22.05M) | 49.35M | 102.62M |
| Free Cash Flow | 70.04M | 119.93M | (4.27M) | 77.41M | 48.91M |
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Intrinsic Alpha fair value
Locked
Current Price
$298.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.